Carfilzomib, a second-generation proteasome inhibitor, is approved for the treatment of relapsed or refractory multiple myeloma, with cardiovascular toxicity being the most common concern. Nevertheless, pulmonary complications have been reported and may compli... ...

请注册登录后继续浏览